Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 116
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00578903 | Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia | ||
| NCT00902044 | Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma | ||
| NCT04219163 | Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen | ||
| NCT01205334 | Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme | ||
| NCT01702961 | Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease | ||
| NCT06198296 | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | ||
| NCT01570283 | ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus | ||
| NCT01713439 | Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL | ||
| NCT00058773 | Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease | ||
| NCT03093350 | TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer | ||
| NCT00953420 | Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes | ||
| NCT01853631 | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) | ||
| NCT01247688 | Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies | ||
| NCT03596086 | HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM | ||
| NCT00040469 | Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies | ||
| NCT00085930 | Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients | ||
| NCT04345601 | Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) | ||
| NCT00058617 | Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL | ||
| NCT00058591 | Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs) | ||
| NCT00062868 | LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma | ||
| NCT01192555 | Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma | ||
| NCT01192464 | EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma | ||
| NCT02439788 | 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA | ||
| NCT01316146 | Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) | ||
| NCT03081910 | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen | ||
| NCT03768310 | CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) | ||
| NCT02973113 | Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) | ||
| NCT00590460 | Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia | ||
| NCT02932956 | Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) | ||
| NCT00703222 | A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells | ||
| NCT02108522 | Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant | ||
| NCT00078533 | Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant | ||
| NCT05134740 | (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). | ||
| NCT00078520 | Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells | ||
| NCT00516087 | LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA) | ||
| NCT01460901 | Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma | ||
| NCT00040482 | High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis | ||
| NCT01247701 | Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies | ||
| NCT02291848 | Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma | ||
| NCT00224354 | Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells | ||
| NCT00048412 | Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H | ||
| NCT07211737 | NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma | ||
| NCT00515957 | Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL) | ||
| NCT01070797 | Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) | ||
| NCT01109095 | CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM | ||
| NCT00586274 | Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT | ||
| NCT00586391 | CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL | ||
| NCT05236764 | Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion | ||
| NCT00069992 | Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML | ||
| NCT02494167 | Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) |
